Should long-haul flights carry antibiotics on board to treat acute bacterial meningitis and meningococcal septicaemia?

Rao, Dingqi; Hamilton, Esther E.; Glennie, Linda; McConnell, Daniel; Bc, Millar; Rj, Rooney; Ce, Goldsmith; Loughrey, Anne; Shields, Michael; Je, Moore

doi:10.1080/09674845.2008.11978130

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concern has led to a recent article that questioned if long-haul flights should carry antibiotics to treat acute bacterial meningitis and meningococcal disease. It concluded that there is a need for airlines to re-evaluate their response to symptoms of these conditions in terms of awareness as well as treatment [32].…”

Section: Air Travelmentioning

confidence: 95%

Meningococcal vaccines: a neglected topic in travel medicine?

Wilder-Smith¹

2009

Expert Review of Vaccines

View full text Add to dashboard Cite

Meningococcal disease is a devastating disease. Regular epidemics, particularly in the African meningitis belt and outbreaks during the Hajj pilgrimage, have caused significant morbidity and mortality. Although meningococcal vaccination is recommended for travelers to these destinations, disease awareness among travelers is generally poor. Case-fatality rates of meningococcal disease are high (10-14%) and the disease can be fatal within 24 h, even when the best healthcare is available. This is particularly relevant to travelers, as gaining timely and accurate diagnosis and treatment is often difficult in foreign countries or remote regions. Given the unpredictable epidemiology of the disease, broad meningococcal vaccination for all ages should be considered for travelers. Conjugate meningococcal vaccines have significant advantages over polysaccharide vaccines, and should be the preferred option for travelers.

show abstract

Section: Air Travelmentioning

confidence: 95%

Meningococcal vaccines: a neglected topic in travel medicine?

Wilder-Smith¹

2009

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…By 10–14 days after diagnosis of the index case, chemoprophylaxis is not recommended. Chemoprophylaxis should be considered for those travelling on an airplane for ≥8 hours close to an index case 34. Hajj pilgrims from the African meningitis belt countries receive meningococcal chemoprophylaxis at the port of entry to reduce carrier rates 35.…”

Section: Clinical Management and Prevention Of Imdmentioning

confidence: 99%

Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease

Bröker

Cooper²,

DeTora

et al. 2011

IDR

View full text Add to dashboard Cite

Worldwide, invasive meningococcal disease affects about 500,000 people annually. Case fatality in developed countries averages 10%, and higher rates are reported in less prosperous regions. According to the World Health Organization, the most important pathogenic serogroups are A, B, C, W-135, X, and Y. Clinical features of invasive meningococcal disease make diagnosis and management difficult. Antibiotic measures are recommended for prophylaxis after exposure and for treatment of invasive meningococcal disease cases; however, resistant strains may be emerging. Vaccines are generally regarded as the best preventative measure for invasive meningococcal disease. Polysaccharide vaccines against serogroups A, C, W-135, and Y using protein conjugation technology have clear advantages over older plain polysaccharide formulations without a protein component. The first quadrivalent meningococcal conjugate vaccine (MenACWY-D) was licensed in the US in 2005. More recently, MenACWY-CRM (Menveo®) was licensed in Europe, the US, the Middle East, and Latin America. MenACWY-CRM uses cross-reactive material 197, a nontoxic mutant of diphtheria toxin, as the carrier protein. MenACWY-CRM offers robust immunogenicity in all age groups, with a tolerability profile similar to that of a plain polysaccharide vaccine. Given its potential for protecting persons from infancy to old age, MenACWY-CRM offers the opportunity to protect broad populations against invasive meningococcal disease. The most optimal strategy for use of the vaccine has to be assessed country by country on the basis of local epidemiology, individual health care systems, and need.

show abstract

Should long-haul flights carry antibiotics on board to treat acute bacterial meningitis and meningococcal septicaemia?

Cited by 2 publications

References 0 publications

Meningococcal vaccines: a neglected topic in travel medicine?

Meningococcal vaccines: a neglected topic in travel medicine?

Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease

Contact Info

Product

Resources

About

Should long-haul flights carry antibiotics on board to treat acute bacterial meningitis and meningococcal septicaemia?

Cited by 2 publications

References 0 publications

Meningococcal vaccines: a neglected topic in travel medicine?

Meningococcal vaccines: a neglected topic in travel medicine?

Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo&reg;) in the context of treatment and prevention of invasive disease

Contact Info

Product

Resources

About

Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease